Why Was Reductil (Sibutramine) Withdrawn from the Market?

For about a decade, Reductil, sold as Meridia in the United States and Canada, was one of the best-known prescription diet pills in the world. Then, within a matter of months in 2010, regulators on two continents pulled it from the market. Many people who took it, or who still see the name online, want a straight answer: what went wrong?

The short version is that a large safety trial found more heart attacks and strokes in people taking the drug than in people taking placebo, and the weight loss it produced was modest. Regulators concluded that the risks outweighed the benefits. The longer version is more interesting, because the story involves an earlier scare, a controversial trial population, and a real disagreement about how to weigh small benefits against rare but serious harms.

This article is a case file of that decision. It is educational and does not replace medical advice.

What sibutramine was and how it worked

Sibutramine was first developed as a possible antidepressant. It belongs to a family of drugs that raise the activity of the brain chemicals serotonin and noradrenaline by blocking their reabsorption into nerve cells. When researchers noticed that it made people feel full sooner and eat less, it was repurposed as a weight loss drug. The U.S. FDA approved it in 1997 as Meridia, and it reached European markets, including the UK, around 1999 under the brand name Reductil.

The usual dose was a single capsule taken once daily. Compared with phentermine, which is meant for short courses, sibutramine was approved for longer-term use, which meant many more people stayed on it for months or years. If you are curious about how the two drugs differ in detail, we cover that in our upcoming comparison, Reductil vs phentermine.

The built-in tension

The very mechanism that curbed appetite also stimulated the cardiovascular system. Noradrenaline raises heart rate and blood pressure. Product labeling and clinical studies recognised that sibutramine could push blood pressure up by a few points and pulse up by several beats per minute on average. For most people that sounds minor, but obesity is itself a condition in which heart disease risk is already elevated. A drug that nudges blood pressure and pulse in the wrong direction has to deliver a clear benefit to justify that cost. That tension sat at the centre of the regulatory debate.

The timeline: how the decision unfolded

When	What happened	Why it matters
1997	FDA approves sibutramine (Meridia) for obesity treatment	Launches the drug in the largest market
About 1999	Reductil becomes available in Europe, including the UK	Global use expands
2002	Concerns about cardiovascular events lead Italy to suspend the drug, triggering a European review; the review allows it to stay on the market with stronger warnings and a requirement for a large outcomes study	Sets up the trial that would later decide its fate
2002 onward	The SCOUT trial begins, studying cardiovascular outcomes in overweight and obese people at high cardiovascular risk	The study designed to answer the safety question
Late 2009	FDA publicly shares early, preliminary findings and begins evaluating the data	First signal that results were worrying
January 2010	European regulators recommend suspending marketing authorisations, and FDA adds stricter contraindications to the label for people with cardiovascular disease	Europe moves first; U.S. tightens use
September 2010	Full SCOUT results are published in the New England Journal of Medicine	The public sees the complete data
October 2010	FDA requests withdrawal, and the manufacturer complies; Canada and other countries also remove it	End of legal prescription sales in major markets

Exact regulatory dates differ slightly by country, because each agency issues its own notices. The overall sequence is what matters: an early warning, a safety trial, then a risk-benefit reversal.

Chapter 1: the earlier scare in 2002

Sibutramine’s troubles did not begin in 2010. In the early 2000s, reports of serious cardiovascular events in people taking the drug, including a small number of deaths, led Italy to suspend sales. That prompted a formal review at the European level. The review concluded that the benefits still outweighed the risks, but it came with conditions: stronger warnings, tighter patient selection, closer blood pressure and pulse monitoring, and a demand for better evidence on long-term heart outcomes.

That last condition is the key. Regulators effectively said, “We will let this continue, but we need a definitive answer about heart safety.” The SCOUT trial was the answer, and it arrived with an unwelcome result.

Chapter 2: the SCOUT trial in plain language

SCOUT stands for Sibutramine Cardiovascular Outcomes. It enrolled nearly ten thousand adults aged 55 or older who were overweight or obese and who already had cardiovascular disease, type 2 diabetes with another risk factor, or both. Participants first received sibutramine for a short lead-in period, and those who tolerated it were randomly assigned to continue it or to switch to placebo, both alongside lifestyle support. Researchers then tracked heart attacks, strokes, cardiac arrest, and cardiovascular death over several years.

The headline finding was that the primary composite outcome occurred more often in the sibutramine group, around 11.4% versus roughly 10.0% for placebo, a relative increase of about 16%. The difference came mainly from higher rates of non-fatal heart attack and non-fatal stroke. Deaths from cardiovascular causes and from all causes were not significantly different between groups.

We unpack the study design, the numbers, and the criticisms in a dedicated explainer: the SCOUT trial explained: Reductil and heart risk. For this article, the key point is simply that the largest and longest safety trial pointed in the wrong direction.

Chapter 3: the controversy over who was studied

This is the part most summaries skip, and it matters for fairness.

By the time SCOUT reported, the drug’s own labeling already advised against using sibutramine in people with established heart disease. SCOUT, however, deliberately enrolled people at high cardiovascular risk, including many who already had heart or vascular disease. That meant the trial tested the drug in a population for whom it was not supposed to be prescribed.

Supporters of the drug, including the manufacturer, argued that the results therefore overstated the risk for appropriately selected patients. Regulators did not dismiss this argument, but they reached a different conclusion for three reasons:

1. Real-world use drifts. Obesity commonly travels with high blood pressure, diabetes, and abnormal cholesterol. In practice, many people prescribed the drug had cardiovascular risk factors, whether or not they met the strict contraindication, and some had undiagnosed disease.
2. The benefit was modest. The average weight loss attributable to the drug was only a few kilograms beyond lifestyle changes alone. Small benefits tolerate very little risk.
3. No proof of safety in a lower-risk group. There was no comparably large outcomes trial showing that the drug was safe in lower-risk people, so regulators could not assume that it was.

This is a classic example of regulatory reasoning under uncertainty. When a drug’s upside is small, even a modest and imperfectly characterised risk can tip the balance.

Chapter 4: the risk-benefit calculation

Think of the decision as a simple ledger.

On the benefit side	On the risk side
Average weight loss of a few kilograms beyond lifestyle changes alone	More non-fatal heart attacks and strokes in the largest trial
Some people lost considerably more than average	Higher blood pressure and heart rate in many users
Possible improvements in some metabolic markers with weight loss	Risk concentrated in people with existing heart disease, a group that is hard to exclude fully in practice
Oral, once-daily convenience	Other side effects, including dry mouth, constipation, sleeplessness, and potential interactions with antidepressants

An important principle here is that weight loss itself is a surrogate goal. What matters to patients is living longer and avoiding heart attacks, strokes, and diabetes complications. When a weight loss drug fails to show a clear improvement in those outcomes and instead shows signs of harm, regulators lose the justification for tolerating its side effects.

Chapter 5: what regulators said and did

Europe

The European Medicines Agency’s scientific committee reviewed the SCOUT data and concluded that the risks were greater than the benefits. It recommended that marketing authorisations for sibutramine-containing medicines be suspended across the EU. National agencies, including the UK’s medicines regulator, told doctors to stop prescribing and pharmacists to stop dispensing, and advised patients to speak with their doctor about alternative approaches.

United States

The FDA first tightened the label, adding a contraindication for people with a history of coronary artery disease, stroke, heart failure, arrhythmia, and certain other cardiovascular conditions. After the full trial results were evaluated, the agency concluded that the drug’s modest weight loss did not justify the added cardiovascular risk, and it asked the manufacturer to withdraw the product. The company agreed. You can read the agency’s statement on the FDA drug safety communication on Meridia.

Elsewhere

Canada, Australia, and numerous other countries took similar action within the same period, and several Asian markets also restricted or removed the drug. Because regulators watch one another’s decisions closely, a verdict from the EU and the U.S. in the same year had global consequences.

Who was most at risk?

Most of the concern focused on people who had or were likely to develop cardiovascular disease. Groups flagged in labeling and safety communications included people with:

• Coronary artery disease, previous heart attack, or angina
• Previous stroke or transient ischaemic attack
• Heart failure or serious arrhythmias
• Peripheral arterial disease
• Poorly controlled high blood pressure
• Type 2 diabetes with additional risk factors, especially in older adults

Sibutramine also had interaction concerns. Because it increases serotonin and noradrenaline activity, combining it with certain antidepressants, migraine medicines, or MAO inhibitors raised the risk of excess serotonin activity, a serious condition. If you want to understand how related antidepressant classes differ, our guide to SSRIs vs SNRIs gives helpful background.

Was it only about the heart?

The cardiovascular findings drove the decision, but sibutramine had other drawbacks that shaped the overall picture:

• Limited efficacy: average results were modest, and some patients had no meaningful response.
• Tolerability: dry mouth, insomnia, constipation, headache, and anxiety were common reasons people stopped.
• Misuse and counterfeit risk: its popularity made it a favourite for illicit adulteration of supplements, a problem that continues today. We explore that in hidden sibutramine in herbal slimming pills.

Not the first, not the last: a pattern of withdrawn weight loss drugs

The history of weight loss medicines includes several cautionary tales, and understanding the pattern helps you evaluate any new product.

Drug	Approximate period	Reason for withdrawal
Fenfluramine and dexfenfluramine	1997	Heart valve abnormalities and pulmonary hypertension
Rimonabant	2008 (Europe)	Serious psychiatric effects, including depression and suicidal thoughts
Sibutramine	2010	Higher rate of non-fatal heart attack and stroke, modest benefit
Lorcaserin (Belviq)	2020 (U.S.)	Possible increase in cancer in a safety trial

Each case involved a drug that appeared reasonable at approval but showed a problem only after large numbers of people used it or after a long outcomes study. For a related comparison with another drug that was pulled, see our guide to Belviq vs phentermine.

What the pattern teaches

1. Short trials miss rare harms. A heart attack signal needs thousands of people followed for years to appear.
2. Surrogate outcomes can mislead. Losing weight does not automatically mean better health outcomes.
3. Drugs that act on brain chemistry affect the whole body. Appetite pathways overlap with heart, mood, and blood pressure pathways.
4. Newer is not automatically safer, and older is not automatically riskier. Evidence over time is what counts.

What if you took Reductil or Meridia?

If you used sibutramine in the past and stopped some time ago, there is usually no specific action needed. The cardiovascular risk observed in the trial related to ongoing use, and it is not known to persist indefinitely after stopping. That said, it is sensible to:

• Mention your past use to your doctor, particularly if you have heart disease risk factors.
• Have your blood pressure, cholesterol, and blood sugar checked on a regular schedule.
• Seek medical care promptly for chest pain, breathlessness, fainting, or signs of stroke, as you would for anyone.

For ideas on supporting heart health through daily habits, our article on natural ways to lower blood pressure is a good starting point, and the broader question of cardiovascular risk from stimulant-type drugs is explored in is Adderall bad for your heart?

What if you still have old capsules, or find it for sale?

Do not take them. Expired capsules may be degraded, and any product sold online as Reductil or sibutramine today is almost certainly unregulated. Authentic stock is no longer being supplied in major markets, so what remains is likely to be counterfeit or of unknown quality. Use a pharmacy take-back programme or local medicine disposal service for leftover pills.

What should replace it?

People who relied on sibutramine did not lose their options. Several approved medicines are available, each with its own benefits, side effects, and suitability. They also work in different ways, from drugs that block fat absorption to hormone-based injections. We review them in detail, with practical guidance on who they suit, in safer approved alternatives to Reductil for weight loss today. If you want to compare with a drug that is still available for short-term use, see realistic weight loss on phentermine and alternatives to phentermine. For a wider view, what medications cause weight loss maps the landscape.

Common misconceptions

Myth	What the evidence shows
“It was banned because it did not work.”	It produced modest weight loss, but the key reason for withdrawal was increased cardiovascular events combined with limited benefit.
“It was pulled because of a few anecdotal cases.”	The decision rested on a large randomised outcomes trial, not anecdotes.
“It was banned only because of politics.”	Independent regulators on several continents reviewed the same data and reached similar conclusions.
“The ban proves all diet pills are dangerous.”	Risk varies by drug. The lesson is to demand strong long-term evidence, not to reject all treatment.
“If it is still online, it must be safe.”	Online availability usually means illegal, unregulated stock of unknown quality.
“Herbal versions are a safe replacement.”	Some so-called herbal products have been found to contain hidden sibutramine and other undeclared drugs.

Questions to ask your doctor if you are considering any weight loss drug

1. How much weight did patients lose on average in the trials, compared with placebo?
2. Was it tested in people like me, in age, heart health, and other conditions?
3. Has it been studied for cardiovascular outcomes, not just weight?
4. What are the most common and the most serious side effects?
5. Does it interact with any of my current medicines?
6. How long am I expected to take it, and what happens when I stop?

Frequently asked questions

Why was Reductil withdrawn in simple terms?

A major safety trial found that people taking it had more non-fatal heart attacks and strokes than people taking placebo, and the extra weight loss it offered was small. Regulators decided the risks outweighed the benefits.

Is Reductil the same as sibutramine and Meridia?

Yes. Sibutramine is the active ingredient. Reductil was the brand name in Europe and many other countries, and Meridia was the brand name in the United States and Canada.

Was sibutramine banned worldwide?

It was withdrawn or suspended in the major regulated markets, including the EU, the U.S., Canada, and Australia, and in many other countries. Regulatory status can differ locally, so check your own national authority if you need certainty.

Can I still get Reductil with a prescription?

Not legally in the major markets. Any source claiming to supply it today is unregulated, and the product may be counterfeit or contaminated.

Did sibutramine cause deaths?

In the SCOUT trial, deaths from cardiovascular causes and from all causes were not significantly different between groups. The excess was in non-fatal heart attacks and strokes, which are serious events with lasting consequences.

Is it safe to have taken it in the past?

The risk seen in the trial related to ongoing use in high-risk people. Past users without heart disease do not usually need special follow-up beyond regular health checks, but mention it to your doctor if you have risk factors or concerns.

Is phentermine the same kind of drug?

No. Phentermine acts mainly by releasing noradrenaline and is approved only for short-term use. It also raises heart rate and blood pressure in some people, and it has its own contraindications. The two drugs are compared in Reductil vs phentermine.

Could sibutramine be reintroduced?

That is very unlikely without a new large trial showing a favourable balance of risks and benefits, and the market has since moved toward drugs with larger weight loss effects.

The bottom line

Reductil was not withdrawn because of rumour or because it was useless. It was withdrawn because the largest and longest study of its cardiovascular safety showed more heart attacks and strokes in the treated group, while the weight loss it delivered was modest. Debates about the trial population were real, but regulators concluded that a drug with small benefits could not carry that risk.

The practical lesson for patients is to look beyond the number on the scale and ask what a drug does for long-term health. If you are choosing a weight loss medicine today, favour options with clear safety data, discuss your heart health honestly with a clinician, and be wary of any product that promises prescription-strength results without prescription-level oversight.

Medical disclaimer: this article is for general education only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional before starting, changing, or stopping any medication.

Sources and further reading

• U.S. FDA: Drug Safety Communication on Meridia (sibutramine)
• New England Journal of Medicine: Effect of Sibutramine on Cardiovascular Outcomes in Overweight and Obese Subjects (SCOUT)
• European Medicines Agency: search “sibutramine” for the 2010 review
• NIDDK: Prescription Medications to Treat Overweight and Obesity